Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling

Wen-Xi Tan,Ge Sun,Meng-Yuan Shangguan,Zhi Gui,Yang Bao,Yu-Feng Li,Zan-Hui Jia
DOI: https://doi.org/10.1038/s41598-020-71153-0
IF: 4.6
2020-09-08
Scientific Reports
Abstract:Abstract Ovarian Cancer (OC) is a highly lethal gynecological cancer which often progresses through acquired resistance against the administered therapy. Cisplatin is a common therapeutic for the treatment of OC patients and therefore it is critical to understand the mechanisms of resistance against this drug. We studied a paired cell line consisting of parental and cisplatin resistant (CR) derivative ES2 OC cells, and found a number of dysregulated lncRNAs, with CHRF being the most significantly upregulated lncRNA in CR ES2 cells. The findings corroborated in human patient samples and CHRF was significantly elevated in OC patients with resistant disease. CHRF was also found to be elevated in patients with liver metastasis. miR-10b was found to be mechanistically involved in CHRF mediated cisplatin resistance. It induced resistance in not only ES2 but also OVCAR and SKOV3 OC cells. Induction of epithelial-to-mesenchymal-transition (EMT) and activation of STAT3 signaling were determined to be the mechanisms underlying the CHRF-miR-10b axis-mediated cisplatin resistance. Down-regulation of CHRF reversed EMT, STAT3 activation and the resulting cisplatin resistance, which could be attenuated by miR-10b. The results were also validated in an in vivo cisplatin resistance model wherein CR cells were associated with increased tumor burden, CHRF downregulation associated with decreased tumor burden and miR-10b again attenuated the CHRF downregulation effects. Our results support a novel role of lncRNA CHRF in cisplatin resistance of OC and establish CHRF-miR-10b signaling as a putative therapeutic target for sensitizing resistant OC cells.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the mechanism of ovarian cancer (OC) developing resistance to cisplatin treatment. Specifically, by establishing cisplatin - resistant ovarian cancer cell lines and analyzing the expression changes of long non - coding RNAs (lncRNAs) and microRNAs (miRNAs) in these cells, the researchers aim to discover specific lncRNAs related to cisplatin resistance and their mechanisms of action. The study found that lncRNA CHRF is significantly up - regulated in cisplatin - resistant ovarian cancer cells, and this up - regulation is related to miR - 10b - mediated epithelial - to - mesenchymal transition (EMT) and the activation of the STAT3 signaling pathway. Therefore, the main purpose of the paper is to reveal the new role of CHRF in cisplatin resistance and explore its potential as a therapeutic target. ### Research Background - **The lethality of ovarian cancer**: Ovarian cancer is one of the most lethal cancers in the female reproductive system, especially in developing countries, where the mortality rate is relatively high. - **Cisplatin resistance**: Cisplatin is a commonly used drug for treating ovarian cancer, but patients often develop resistance to cisplatin, which is a major obstacle in clinical treatment. - **The role of non - coding RNAs**: In recent years, more and more studies have shown that non - coding RNAs (such as lncRNAs and miRNAs) play important roles in the occurrence and development of cancer, especially in chemotherapy resistance. ### Research Methods 1. **Cell culture**: Three ovarian cancer cell lines, ES2, OVCAR3 and SKOV3, were used. By gradually increasing the cisplatin concentration, a cisplatin - resistant ES2 cell line (CR cells) was established. 2. **lncRNA and miRNA expression analysis**: The expression changes of lncRNAs and miRNAs in CR cells were detected by quantitative RT - PCR. 3. **Functional verification**: By down - regulating CHRF or over - expressing miR - 10b, the changes in cell sensitivity to cisplatin were observed. 4. **In vivo experiments**: A mouse model was used to verify the roles of CHRF and miR - 10b in cisplatin resistance. ### Main Findings - **Up - regulation of CHRF**: In cisplatin - resistant ovarian cancer cells, CHRF is significantly up - regulated. - **Up - regulation of miR - 10b**: miR - 10b is also significantly up - regulated in cisplatin - resistant cells. - **EMT and STAT3 signaling pathways**: CHRF induces EMT and activates the STAT3 signaling pathway by up - regulating miR - 10b, thus leading to cisplatin resistance. - **In vivo verification**: In a mouse model, down - regulating CHRF can reduce tumor growth, and over - expressing miR - 10b can reverse this effect. ### Conclusion This study reveals the new role of lncRNA CHRF in cisplatin resistance in ovarian cancer and discovers that CHRF induces EMT and activates the STAT3 signaling pathway by up - regulating miR - 10b, thus leading to cisplatin resistance. These findings provide potential targets for the development of new treatment strategies.